Capricor Therapeutics, Inc. (CAPR) stock
CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.53−0.71 (-6.93%)
Close on Nov 13, 2026Market cap $554.07MP/E –Yield –
Capricor Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Capricor Therapeutics's profit margin for the twelve months ending Dec 31, 2024 was -181.7%. For fiscal 2024 it was -181.7%, against -88.5% the year before. The highest annual figure on record is 91.2% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -181.7% | −93.2 |
| FY2023 | Dec 31, 2023 | -88.5% | +1048.8 |
| FY2022 | Dec 31, 2022 | -1137.4% | +7038.5 |
| FY2021 | Dec 31, 2021 | -8175.9% | −3773.9 |
| FY2020 | Dec 31, 2020 | -4401.9% | −3641.6 |
| FY2019 | Dec 31, 2019 | -760.4% | +148.5 |
| FY2018 | Dec 31, 2018 | -908.9% | −1000.1 |
| FY2017 | Dec 31, 2017 | 91.2% | +561.5 |
| FY2016 | Dec 31, 2016 | -470.3% | −237.3 |
| FY2015 | Dec 31, 2015 | -233.0% | −103.1 |
| FY2014 | Dec 31, 2014 | -129.9% | +1637.1 |
| FY2013 | Dec 31, 2013 | -1767.0% | −707.5 |
| FY2012 | Dec 31, 2012 | -1059.5% | −974.6 |
| FY2011 | Dec 31, 2011 | -84.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -63.9% | −57.6 |
| Q3 FY2024 | Sep 30, 2024 | -555.2% | −451.9 |
| Q2 FY2024 | Jun 30, 2024 | -277.0% | −88.9 |
| Q1 FY2024 | Mar 31, 2024 | -199.6% | +60.5 |
| Q4 FY2023 | Dec 31, 2023 | -6.3% | +798.0 |
| Q3 FY2023 | Sep 30, 2023 | -103.3% | +297.0 |
| Q2 FY2023 | Jun 30, 2023 | -188.0% | +2138.6 |
| Q1 FY2023 | Mar 31, 2023 | -260.1% | +12362.2 |
| Q4 FY2022 | Dec 31, 2022 | -804.3% | +6420.2 |
| Q3 FY2022 | Sep 30, 2022 | -400.3% | +22787.3 |
| Q2 FY2021 | Jun 30, 2021 | -2326.6% | +4660.7 |
| Q1 FY2021 | Mar 31, 2021 | -12622.3% | −11499.6 |
| Q4 FY2020 | Dec 31, 2020 | -7224.5% | −6562.9 |
| Q3 FY2020 | Sep 30, 2020 | -23187.6% | −22056.8 |
| Q2 FY2020 | Jun 30, 2020 | -6987.3% | −6488.6 |
| Q1 FY2020 | Mar 31, 2020 | -1122.7% | −29.8 |
| Q4 FY2019 | Dec 31, 2019 | -661.6% | −158.6 |
| Q3 FY2019 | Sep 30, 2019 | -1130.8% | +755.7 |
| Q2 FY2019 | Jun 30, 2019 | -498.7% | +522.1 |
| Q1 FY2019 | Mar 31, 2019 | -1093.0% | −175.2 |
| Q4 FY2018 | Dec 31, 2018 | -503.0% | −3089.2 |
| Q3 FY2018 | Sep 30, 2018 | -1886.5% | −1013.5 |
| Q2 FY2018 | Jun 30, 2018 | -1020.8% | −672.3 |
| Q1 FY2018 | Mar 31, 2018 | -917.7% | −501.5 |
| Q4 FY2017 | Dec 31, 2017 | 2586.2% | +3084.4 |
| Q3 FY2017 | Sep 30, 2017 | -873.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -348.4% | – |
| Q1 FY2017 | Mar 31, 2017 | -416.3% | – |
| Q4 FY2016 | Dec 31, 2016 | -498.2% | – |
See a number that looks wrong?